NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
NeuroBo Pharmaceuticals | DEF 14A: Definitive information statements
NeuroBo Pharmaceuticals | 8-K: NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation
NeuroBo Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating Da-1241 for the Treatment of Mash
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement
NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals Submits Ind Application to the Fda for a Phase 1 Clinical Trial of Da-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc Posted an Updated Corporate Presentation
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
No Data